Brief: Phio Pharmaceuticals Presents New In Vivo Data At The 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy And Safety Potential Over Other Therapeutic Approaches
04/06/2021 13:37
June 4 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS PRESENTS NEW IN VIVO DATA AT THE 2021
ASCO
ANNUAL MEETING SHOWING DUAL-TARGETING INTASYL OFFERS INCREASED
EFFICACY AND SAFETY POTENTIAL OVER OTHER THERAPEUTIC APPROACHES
Source text for Eikon: ID:nPn8v0CZma
Further company coverage: PHIO.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing